ArticleMaterials today. Bio2025
"Top-down and Bottom-up" cholesterol-depleting biomimetic nanoparticle for enhancing sonodynamic therapy against hepatocellular carcinoma.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ZIF-8 Nanodrug Delivery Systems: Construction Strategies, Functional Modifications, and Advances in Synergistic Tumor Therapy.International journal of nanomedicine · 2026Review
- Hollow CuInternational journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesterol depletion in tumor cells has been demonstrated as an effective strategy for cancer therapy. Previous studies have shown that cholesterol oxidase (COD) could promote cholesterol consumption. However, these tumor cells typically upregulate cholesterol synthesis as a compensatory mechanism to meet the rapid proliferation demands. To address this issue, we synthesized HM/ZIF-8@COD/IR820 nanoparticle, which simultaneously facilitates cholesterol depletion and inhibits cholesterol synthesis to enhance sonodynamic therapy against hepatocellular carcinoma (HCC). This HM/ZIF-8@COD/IR820 biomimetic nanoparticle was constructed by encapsulating cholesterol oxidase (COD) and the sonosensitizer indocyanine green (IR820) into ZIF-8 nanoparticle, followed by coating with a hybrid cell membrane from tumor cells and erythrocyte membrane. The hybrid membrane provides tumor-targeting capability, enabling HM/ZIF-8@COD/IR820 nanoparticle homes to Hepa1-6 tumor and disassembles in response to the acidic microenvironment and ultrasound stimulation. In vitro and in vivo studies confirmed significant cholesterol depletion and alleviation of hypoxia in Hepa1-6 cells. Upon ultrasound activation, a significant amount of reactive oxygen species (ROS) was generated, thereby enhancing the therapeutic effect on the inoculated tumors. Non-targeted metabolomics analysis further validated the downregulation of cholesterol metabolism-related pathways, which was consistent with the Filipin staining results observed in cellular experiments. Importantly, Hepa1-6 tumor growth was significantly suppressed and the inhibition rate reached 90%. These findings highlight HM/ZIF-8@COD/IR820 as a promising biomimetic nanoparticle orchestrates a two-pronged attack on hepatocellular carcinoma cholesterol metabolism: top-down suppression of cholesterol biosynthetic pathways, and bottom-up elimination of existing cholesterol stores, yielding outstanding therapeutic effects against HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.